Roy Herbst, MD, PhD: Adjuvant Osimertinib for EGFR-Mutated Non-Small Cell Lung Cancer

Recently, the FDA approved osimertinib (Tagrisso®, AstraZeneca) as the first adjuvant therapy for patients with surgically resected early-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. In this interview, Roy Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and lead investigator of the ADAURA trial, on which the approval was based, speaks with i3 Health about the significance of the approval of osimertinib for this patient populati...
Continue reading

Adjuvant Osimertinib Approved for EGFR-Mutated Non-Small Cell Lung Cancer

The FDA has approved osimertinib (Tagrisso®, AstraZeneca) for patients with surgically resected early-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. Previously approved for the first-line treatment of metastatic EGFR-mutated disease, osimertinib is the first adjuvant therapy to be approved for patients with EGFR-mutated NSCLC. The approval was based on the phase 3 ADAURA trial (NCT02511106). "Approximately 30% o...
Continue reading

Osimertinib for EGFR-Mutated Advanced NSCLC: An Interview with Suresh S. Ramalingam, MD

The treatment of advanced-stage non-small cell lung cancer (NSCLC) has improved steadily in the past few years, and individualized therapy for patients with mutations in the epidermal growth factor receptor (EGFR) is applied in routine clinical practice. While EGFR-mutated NSCLC is effectively treated with tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, there is a need to develop more effective treatments to improve outcomes in these patients. In a study now published in The Ne...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.